Risk-Stratified Stroke Prevention with SGLT2 Inhibitors: A Meta-Analysis of ASCVD-Dependent Efficacy

Selected angle: source

One-sentence thesis

The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

The stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications.

Known / obvious (do not republish): SGLT2 inhibitors reduce cardiovascular events in type 2 diabetes mellitus; SGLT2 inhibitors lower blood pressure and body weight in heart failure patients

Real tension: Significant stroke reduction in type 2 diabetes with cardiovascular disease (HR 0.83, fact_id 182560) versus non-significant reduction in patients without established ASCVD (RR 0.84, fact_id 175143)

Evidence receipts

• fact_id=182560 (A_core) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836
• fact_id=175143 (A_core) — stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29) doi=10.1161/jaha.123.030578
• fact_id=94845 (A_core) — The estimate for kidney failure in participants with eGFR <30 ml/min per 1.73 m 2 (hazard ratio, 0.67; 95% CI, 0.35 to 1.27) doi=10.2215/cjn.10140620
• fact_id=92691 (A_core) — The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59–0.86) doi=10.1161/circulationaha.120.050391
• fact_id=148351 (A_core) — hazard ratio, 0.74 [95% CI, 0.58–0.92] doi=10.1161/circulationaha.122.060511

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact.

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.